0
Slide Presentations: Monday, November 1, 2010 |

Role of Immunomodulator Tinocordin in Sputum-Positive Fresh Cases of Pulmonary Tuberculosis FREE TO VIEW

Pramod Sood, MD; Dr S.K. Ludhadia, MD; Dr Sandeep Puri, MD; Dr Gunchan Paul, MD
Author and Funding Information

Dayanand Medical College, Ludhiana, India



Chest. 2010;138(4_MeetingAbstracts):749A. doi:10.1378/chest.10463
Text Size: A A A
Published online

Abstract

PURPOSE: To evaluate the role of Tinocordin (Tinospora Cordifolia) as immunomodulator in fresh cases of sputum positive pulmonary Tuberculosis.

METHODS: Study was a prospective Randomized control trial carried out in 100 sputum positive pulmonary tuberculosis admitted in a tertiary care teaching hospital from January 1999-april 2000. .The patients was randomized into 2 groups -one group received Anti tubercular drugs-Rifampicin, Isoniazid, Ethambutol, and Pyrazinamide.Other group received Anti tubercular treatment plus Tablet Tinocordin 500mgTDS for first two months. The patients were followed at 15,30,and 60 Days and assessed for Clinical Improvement, Weight gain, Radiological Improvement, Hematological parameters, sputum conversion and side effects if any On the Basis of final results at the end of 2 months the patients was divided into 2 categories based on sputum conversion, clinical improvement > 80%, and radiological improvement >50%-Satisfactory all three criteria are met and Unsatisfactory if the above criteria are not met.

RESULTS: Clinical Improvement at 15,30and 60 days was 23%,48%,and 73% study group v/s 16%,31%and 57% respectively in the control group and was statistically significant Mean Radiological improvement in study group at 30 and 60 days was 26.1 and 55.5.v/s 23.24 and 46.96 respectively in the control , this difference was statistically significant at 60 days.(p<0.05)Sputum conversion was achieved in 46%, 74% ,90% in the study group v/s 22%, 58%, 76% at 15, 30 and 60 days respectively in the control group and was at all time intervals statistically significant (p<0.001) Results at the end of 2 months showed satisfactory response in 69.56 % patients in study group v/s 30.61% in control group.The drug had minimal side effects(11%)-constipation (2.17%) rash and itching (4.34%) and increased frequency of micturation (4.34%).

CONCLUSION: The patients in Tinocordin group showed significantly better clinically ,radiological improvement , and early sputum conversion at 15, 30 and 60 days.

CLINICAL IMPLICATIONS: Tinocordin can be used as an adjuvant immunomodulator along with antitubercular drugs safely in treatment of tuberculosis.

DISCLOSURE: Pramod Sood, No Financial Disclosure Information; No Product/Research Disclosure Information

08:00 AM - 09:15 AM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543